Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Apremilast shows promise for several skin conditions but needs more research.

Rituximab may cause skin issues, but baricitinib can help improve them.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Biologics for severe asthma have known side effects, but some new risks need more study.

Dupilumab may help treat alopecia areata without needing high IgE levels.

Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.

Hydroxychloroquine helped improve scleromyxoedema in patients, but caused side effects in some.

Chronic cutaneous lupus erythematosus should be considered when acne treatments don't work.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Rituximab improved her dermatomyositis better than usual treatments.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Tofacitinib may help treat hair loss in children with alopecia areata.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.

Ruxolitinib can cause a delayed skin reaction on the nose.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.